MARKET

GRFS

GRFS

Grifols
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.02
-0.35
-2.14%
Opening 14:17 02/26 EST
OPEN
15.29
PREV CLOSE
16.37
HIGH
16.13
LOW
15.23
VOLUME
1.04M
TURNOVER
--
52 WEEK HIGH
24.58
52 WEEK LOW
13.40
MARKET CAP
4.13B
P/E (TTM)
12.91
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Sector Update: Health Care
MT Newswires · 5h ago
Grifols Reports Lower Earnings, Higher Revenue in FY20; Shares Fall
MT Newswires · 6h ago
Spain's Grifols 2020 net profit falls 1.1% due to coronavirus impact
reuters.com · 11h ago
Bleeding Disorders Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Market Insight Reports · 1d ago
Kepler Capital Sticks to Its Hold Rating for Grifols SA (GRFS)
Kepler Capital analyst Dariusz Ubik maintained a Hold rating on Grifols SA (GRFS) on February 22 and set a price target of EUR24.20. The company's shares
SmarterAnalyst · 2d ago
Grifols PharmacyKeeper ranked No. 1 as 'Best in KLAS' for fifth consecutive year
, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today announced it has ranked No. 1 in IV Workfl...
PR Newswire - PRF · 3d ago
Hemophilia Treatment Market 2020 | Price Trends, Industry Overview, Growth and Forecast To 2027
Japan, Japan, Mon, 22 Feb 2021 01:43:47 / Comserve Inc. / -- Competitive Analysis: Baxter International, Inc., Grifols SA, CSL Ltd., Octapharma AG, Novo...
Comserve · 4d ago
AACSB Announces 2021 Class of Influential Leaders
Sixth annual Influential Leaders initiative recognizes 25 outstanding business school graduates for contributions to societyTAMPA, Fla. 16, 2021 /CNW/ -- AACSB International (AACSB)—the world's largest business education alliance—announces today its 2021 C...
CNW Group · 02/16 14:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GRFS. Analyze the recent business situations of Grifols through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GRFS stock price target is 32.65 with a high estimate of 41.48 and a low estimate of 23.83.
EPS
Institutional Holdings
Institutions: 315
Institutional Holdings: 108.23M
% Owned: 41.95%
Shares Outstanding: 258.01M
TypeInstitutionsShares
Increased
65
12.38M
New
53
545.18K
Decreased
50
14.44M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.03%
Pharmaceuticals & Medical Research
-0.89%
Key Executives
Non-Executive Chairman
Victor Grifols Roura
Co-Chief Executive Officer/Executive Director
Victor Grifols Deu
Co-Chief Executive Officer/Executive Director
Raimon Grifols Roura
Non-Executive Vice Chairman
Thomas Daga Glanzmann
Non-Executive Vice Chairman
Thomas Glanzmann
Chief Financial Officer
Alfredo Arroyo Guerra
Corporate Executive
PETER ALLEN
Corporate Executive
Joel Abelson
Corporate Executive
Albert Coma-Cros
Corporate Executive
Gregory Gene Rich
Corporate Executive
Albert Grifols Roura
Corporate Executive
Eduardo Raimundo Herrero Jimenez
Corporate Executive
ROBERT JAGT
Corporate Executive
Jose Oriol Dunach
Corporate Executive
Miguel Pascual Montblanch
Corporate Executive
Carsten Schroeder
Chief Human Resource Officer
Mateo Borras Humbert
Chief Technology Officer
Javier Sueiras Gil
Vice President
Vicente Blanquer Torre
Vice President
Matt Murawski
Vice President
Nuria Pascual Lapena
Vice President
Teresa Rione
General Counsel
David Bell
Managing Director
Luis Twose Garcon
Other
Daniel Fleta
Other
Lafmin Morgan
Secretary
Nuria Martin Barnes
Assistant Secretary/Director
Tomas Daga Gelabert
Lead Director/Independent Director
Inigo Sanchez Asiain Mardones
Director
Ramon Riera Roca
Independent Director
Marla Elizabeth Salmon
Independent Director
Enriqueta Felip Font
Independent Director
Luis Isasi Fernandez de Bobadilla
Independent Director
Steven Mayer
Independent Director
Carina Szpilka Lazaro
Independent Director
Belen Villalonga Morenes
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.143166
10/30/2020
10/31/2019
Dividend USD 0.169716
12/02/2019
05/29/2019
Dividend USD 0.175638
06/07/2019
11/07/2018
Dividend USD 0.22789
11/30/2018
05/25/2018
Dividend USD 0.250975
06/01/2018
--
Dividend USD 0.212979
12/01/2017
--
Dividend USD 0.163528
05/30/2017
--
Dividend USD 0.193644
12/05/2016
--
Dividend USD 0.162059
06/02/2016
--
Dividend USD 0.384765
12/10/2015
--
Dividend USD 0.341846
06/08/2015
--
Dividend USD 0.312792
12/04/2014
05/30/2014
Dividend USD 0.286887
06/05/2014
05/24/2013
Dividend USD 0.258668
06/05/2013
05/17/2013
Dividend USD 0.01283
05/29/2013
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

Webull offers kinds of Grifols SA - ADR stock information, including NASDAQ:GRFS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRFS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GRFS stock methods without spending real money on the virtual paper trading platform.